BioXcel Therapeutics
BTAI
BTAI
108 hedge funds and large institutions have $378M invested in BioXcel Therapeutics in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 37 increasing their positions, 32 reducing their positions, and 32 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
25% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 32
38% less call options, than puts
Call options by funds: $4.94M | Put options by funds: $7.94M
Holders
108
Holding in Top 10
–
Calls
$4.94M
Puts
$7.94M
Top Buyers
| 1 | +$25.7M | |
| 2 | +$7.96M | |
| 3 | +$6.75M | |
| 4 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
+$6.54M |
| 5 |
State Street
Boston,
Massachusetts
|
+$5.32M |
Top Sellers
| 1 | -$17.3M | |
| 2 | -$15.5M | |
| 3 | -$4.01M | |
| 4 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$1.73M |
| 5 |
ACA
Apis Capital Advisors
New York
|
-$1.55M |